Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9061)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2016 (publication date) through Feb 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang AQ, Zheng YC, Du J, Zhu CP, Huang HC, Wang SS, Wu LC, Wan XS, Zhang HH, Miao RY, Sang XT, Zhao HT. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed. World J Gastroenterol 2016; 22(18): 4459-4465 [PMID: PMC4858629 DOI: 10.3748/wjg.v22.i18.4459] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i18/4459.htm |
| Number | Citing Articles |
| 1 |
Hao Zhang, Xiaojiong Yu, Jian Xu, Juan Li, Yao Zhou. Combined hepatocellular-cholangiocarcinoma. Medicine 2019; 98(38): e17102 doi: 10.1097/MD.0000000000017102
|
| 2 |
Takashi Ito, Takamichi Ishii, Haruhiko Takeda, Shinji Sumiyoshi, Katsuhiro Tomofuji, Satoshi Wakama, Kenta Makino, Hiroshi Horie, Ken Kumagai, Atsushi Takai, Elena Yukie Uebayashi, Satoshi Ogiso, Ken Fukumitsu, Hironori Haga, Hiroshi Seno, Etsuro Hatano. Comprehensive analyses of the clinicopathological features and genomic mutations of combined hepatocellular‐cholangiocarcinoma. Hepatology Research 2024; 54(1): 103 doi: 10.1111/hepr.13965
|
| 3 |
Anqiang Wang, Liangcai Wu, Jianzhen Lin, Longzhe Han, Jin Bian, Yan Wu, Simon C. Robson, Lai Xue, Yunxia Ge, Xinting Sang, Wenze Wang, Haitao Zhao. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nature Communications 2018; 9(1) doi: 10.1038/s41467-018-03276-y
|
| 4 |
Seong Kyun Na, Gwang Hyeon Choi, Han Chu Lee, Yong Moon Shin, Jihyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Heather Francis. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLOS ONE 2018; 13(6): e0198138 doi: 10.1371/journal.pone.0198138
|
| 5 |
Y. Wang, Q. Yang, S. Li, R. Luo, S. Mao, J. Shen. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clinical Radiology 2019; 74(5): 407.e1 doi: 10.1016/j.crad.2019.01.016
|
| 6 |
Hideo Ohuchi, Yohsuke Hayama, Kimiko Nakajima, Kenichi Kurosaki, Isao Shiraishi, Michikazu Nakai. Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation. Journal of the American Heart Association 2021; 10(4) doi: 10.1161/JAHA.120.016617
|
| 7 |
Laura Broutier, Gianmarco Mastrogiovanni, Monique MA Verstegen, Hayley E Francies, Lena Morrill Gavarró, Charles R Bradshaw, George E Allen, Robert Arnes-Benito, Olga Sidorova, Marcia P Gaspersz, Nikitas Georgakopoulos, Bon-Kyoung Koo, Sabine Dietmann, Susan E Davies, Raaj K Praseedom, Ruby Lieshout, Jan N M IJzermans, Stephen J Wigmore, Kourosh Saeb-Parsy, Mathew J Garnett, Luc JW van der Laan, Meritxell Huch. Human primary liver cancer–derived organoid cultures for disease modeling and drug screening. Nature Medicine 2017; 23(12): 1424 doi: 10.1038/nm.4438
|
| 8 |
Naoki Yagi, Toshihiro Suzuki, Shoichi Mizuno, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Shin Kobayashi, Naoto Gotohda, Genichiro Ishii, Tetsuya Nakatsura. Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Cancer Science 2022; 113(5): 1564 doi: 10.1111/cas.15313
|
| 9 |
Kedar Deodhar. PET/CT in Hepatobiliary and Pancreatic Malignancies. 2018; : 13 doi: 10.1007/978-3-319-60507-4_2
|
| 10 |
Abdullah O. Alenezi, Satheesh Krishna, Mishal Mendiratta-Lala, Ania Z. Kielar. Imaging and Management of Liver Cancer. Seminars in Ultrasound, CT and MRI 2020; 41(2): 122 doi: 10.1053/j.sult.2019.12.002
|
| 11 |
Yu-Ting Shen, Wen-Wen Yue, Hui-Xiong Xu. Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma. Abdominal Radiology 2023; 48(6): 2019 doi: 10.1007/s00261-023-03879-0
|
| 12 |
Nancy M Joseph, Christos G Tsokos, Sarah E Umetsu, A Hunter Shain, Robin K Kelley, Courtney Onodera, Sarah Bowman, Eric Talevich, Linda D Ferrell, Sanjay Kakar, Gregor Krings. Genomic profiling of combined hepatocellular‐cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. The Journal of Pathology 2019; 248(2): 164 doi: 10.1002/path.5243
|
| 13 |
Jitao Wang, Zhi Li, Yong Liao, Jinlong Li, Hui Dong, Hao Peng, Wenjing Xu, Zhe Fan, Fengxiao Gao, Chengyu Liu, Dengxiang Liu, Yewei Zhang. Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.686972
|
| 14 |
Edward C. Lo, Adam N. Rucker, Michael P. Federle. Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation. Seminars in Radiation Oncology 2018; 28(4): 267 doi: 10.1016/j.semradonc.2018.06.010
|
| 15 |
Shahid A. Khan, Simona Tavolari, Giovanni Brandi. Cholangiocarcinoma: Epidemiology and risk factors. Liver International 2019; 39(S1): 19 doi: 10.1111/liv.14095
|
| 16 |
Valentina Leone, Adnan Ali, Achim Weber, Darjus Felix Tschaharganeh, Mathias Heikenwalder. Liver Inflammation and Hepatobiliary Cancers. Trends in Cancer 2021; 7(7): 606 doi: 10.1016/j.trecan.2021.01.012
|
| 17 |
Yasuyuki Shigematsu, Gulanbar Amori, Hiroaki Kanda, Yu Takahashi, Yutaka Takazawa, Kengo Takeuchi, Kentaro Inamura. Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Archiv 2022; 481(2): 253 doi: 10.1007/s00428-022-03318-3
|
| 18 |
Xiaolong Wang, Wentao Wang, Xijuan Ma, Xin Lu, Shaodong Li, Mengsu Zeng, Kai Xu, Chun Yang. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?. European Radiology 2020; 30(10): 5337 doi: 10.1007/s00330-020-06861-2
|
| 19 |
Po-Da Chen, Li-Ju Chen, Yao-Jen Chang, Yun-Jau Chang. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study. The Oncologist 2021; 26(10): e1774 doi: 10.1002/onco.13893
|
| 20 |
Johannes Eschrich, Zuzanna Kobus, Dominik Geisel, Sebastian Halskov, Florian Roßner, Christoph Roderburg, Raphael Mohr, Frank Tacke. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives. Cancers 2023; 15(1): 301 doi: 10.3390/cancers15010301
|
| 21 |
Archana Rastogi. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World Journal of Gastroenterology 2018; 24(35): 4000-4013 doi: 10.3748/wjg.v24.i35.4000
|
| 22 |
|
| 23 |
Aurélie Beaufrère, Julien Calderaro, Valérie Paradis. Combined hepatocellular-cholangiocarcinoma: An update. Journal of Hepatology 2021; 74(5): 1212 doi: 10.1016/j.jhep.2021.01.035
|
| 24 |
Gui-Min Hou, Hai-ling Liu, Hong Wu, Yong Zeng. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Annals of Surgical Oncology 2021; 28(12): 7647 doi: 10.1245/s10434-021-09949-1
|
| 25 |
Mukul Vij, Fadl H Veerankutty, Ashwin Rammohan, Mohamed Rela. Combined hepatocellular cholangiocarcinoma: A clinicopathological update. World Journal of Hepatology 2024; 16(5): 766-775 doi: 10.4254/wjh.v16.i5.766
|
| 26 |
Mohamad F Ayas, Saif Affas, Zayd Ayas, Momal Chand, Tarik Hadid. Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer. Cureus 2021; doi: 10.7759/cureus.18224
|
| 27 |
Lun Lu, ChenCai Zhang, Xian Yu, Ling Zhang, YaYuan Feng, YuXian Wu, JinJu Xia, Xue Chen, RuiPing Zhang, Juan Zhang, Ningyang Jia, SiSi Zhang, Alessandro Granito. The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/4691172
|
| 28 |
Matteo Renzulli, Daryl Ramai, Jameel Singh, Samridhi Sinha, Nicolò Brandi, Anna Maria Ierardi, Elisa Albertini, Rodolfo Sacco, Antonio Facciorusso, Rita Golfieri. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers 2021; 13(13): 3336 doi: 10.3390/cancers13133336
|
| 29 |
N. Machairas, P. Stamopoulos, I.D. Kostakis, Z. Garoufalia, A. Paspala, P. Tsaparas, G.C. Sotiropoulos. Mixed Hepatocellular Cholangiocarcinoma: A Review of Long-Term Outcomes Following Liver Transplantation. Transplantation Proceedings 2019; 51(2): 437 doi: 10.1016/j.transproceed.2019.01.073
|
| 30 |
Ka Wing Ma, Kenneth Siu Ho Chok. Importance of surgical margin in the outcomes of hepatocholangiocarcinoma. World Journal of Hepatology 2017; 9(13): 635-641 doi: 10.4254/wjh.v9.i13.635
|
| 31 |
Zhen Yang, Guangjun Shi. Survival outcomes of combined hepatocellular‐cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population‐based cohort study. Cancer Medicine 2022; 11(3): 692 doi: 10.1002/cam4.4474
|
| 32 |
Deborah Malvi, Dario de Biase, Silvia Fittipaldi, Marco Grillini, Michela Visani, Annalisa Pession, Antonia D'Errico, Francesco Vasuri. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate‐cell carcinoma?. Histopathology 2020; 76(2): 265 doi: 10.1111/his.13966
|
| 33 |
Christopher D. Malone, Wendell Gibby, Richard Tsai, Seung Kwon Kim, Samantha Lancia, Olaguoke Akinwande, Raja S. Ramaswamy. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma. Journal of Vascular and Interventional Radiology 2020; 31(5): 701 doi: 10.1016/j.jvir.2019.09.028
|
| 34 |
Takamichi Ishii, Takashi Ito, Shinji Sumiyoshi, Satoshi Ogiso, Ken Fukumitsu, Satoru Seo, Kojiro Taura, Shinji Uemoto. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World Journal of Surgical Oncology 2020; 18(1) doi: 10.1186/s12957-020-02099-w
|
| 35 |
Aldona Kasprzak, Agnieszka Adamek. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis. International Journal of Molecular Sciences 2019; 20(6): 1288 doi: 10.3390/ijms20061288
|
| 36 |
Yingzhe Hu, Zheng Peng, Mengdi Qiu, Lingling Xue, Haozhen Ren, Xingyu Wu, Xinhua Zhu, Yitao Ding. Developing biotechnologies in organoids for liver cancer. Biomedical Technology 2025; 9: 100067 doi: 10.1016/j.bmt.2024.100067
|
| 37 |
Adrien Holzgreve, Harun Ilhan, Lena M. Unterrainer, Malte Kircher, Constantin Lapa, Johanna S. Enke. Primäre und sekundäre Lebertumore – aus Sicht der Nuklearmedizin. Angewandte Nuklearmedizin 2023; 46(04): 331 doi: 10.1055/a-2178-6089
|
| 38 |
Francisco Nolasco, Gilton Marques Fonseca, Evandro S. de Mello, Jaime Arthur Pirolla Kruger, Vagner Birk Jeismann, Fabio Ferrari Makdissi, Fabricio Ferreira Coelho, Venancio A. F. Alves, Paulo Herman. Prognostic Impact of the Cholangiolar Component in Combined Hepatocellular‐Cholangiocarcinoma: Insights From a Western Single‐Center Study. Journal of Surgical Oncology 2024; doi: 10.1002/jso.27955
|
| 39 |
Magnus Rizell, Fredrik Åberg, Mats Perman, Lars Ny, Liselotte Stén, Farida Hashimi, Joar Svanvik, Per Lindnér. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. Case Reports in Oncology 2020; 13(1): 478 doi: 10.1159/000507320
|
| 40 |
Badawy A. Abdulaziz, Waleed El Agawy, Mohamed El-Tantawy Ibrahim, Medhat A. Khalil, Walid A. Abdel Halim.
Significance of Carbohydrate Antigen 19-9 as a biomarker in Hepatocellular Carcinoma and Cholangiocarcinoma
. The Open Biomarkers Journal 2021; 11(1): 39 doi: 10.2174/1875318302111010039
|
| 41 |
Yiannis Petros Dimopoulos, Emily R Winslow, Aiwu Ruth He, Metin Ozdemirli. Hepatocellular carcinoma with biliary and neuroendocrine differentiation: A case report. World Journal of Clinical Oncology 2021; 12(4): 262-271 doi: 10.5306/wjco.v12.i4.262
|
| 42 |
Dimitrios Schizas, Aikaterini Mastoraki, Eleni Routsi, Michail Papapanou, Dimitrios Tsapralis, Pantelis Vassiliu, Konstantinos Toutouzas, Evangelos Felekouras. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary & Pancreatic Diseases International 2020; 19(6): 515 doi: 10.1016/j.hbpd.2020.07.004
|